GSK CEO Andrew Witty
Media playback is unsupported on your device

Malaria vaccine trial raises hope

A malaria vaccine has shown promising results in a clinical trial in Africa.

Infants given the prototype vaccine had about half the risk of getting malaria compared with those who did not receive the jab, say researchers.

The vaccine, known as RTS,S, is one of two experimental malaria vaccines being tested around the world.

GlaxoSmithKline have researched the vaccine and CEO Andrew Witty lauded the work as an "incredible scientific achievement".

  • 18 Oct 2011
  • From the section Health
Go to next video: How SMS is helping Tanzania battle malaria